Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rezolute, Inc. (RZLT : NSDQ)

• Company Description    Rezolute, Inc. is a biopharmaceutical company specializing in the development of drug therapies for metabolic and orphan diseases. The Company's products include AB101, RZ358, RZ402 and RZ602 which are in clinical stage. Rezolute, Inc., formerly known as AntriaBio, Inc., is based in LOUISVILLE, United States. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $7.69 Daily Weekly Monthly 20 Day Moving Average: 820,391 shares Shares Outstanding: 87.00 (millions) Market Capitalization: $669.00 (millions) Beta: 0.03 52 Week High: $8.34 52 Week Low: $2.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.04% 16.95% 12 Week 88.94% 71.63% Year To Date 56.94% 45.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 275 SHORELINE DRIVE SUITE 500 - REDWOOD CITY,CA 94065 USA ph: 650-206-4507 fax: - investor-relations@rezolutebio.com http://www.rezolutebio.com

• General Corporate Information    Officers Nevan Charles Elam - Chief Executive Officer and Chairman of the Board Gil Labrucherie - Director Nerissa Kreher - Director Philippe Fauchet - Director Young-Jin Kim - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76200L309 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/18/25 Share - Related Items Shares Outstanding: 87.00 Most Recent Split Date: 10.00 (0.02:1) Beta: 0.03 Market Capitalization: $669.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.64 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 20.59% vs. Previous Quarter: -22.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -70.09 12/31/24 - -70.27 ROA 06/30/25 - - 03/31/25 - -63.08 12/31/24 - -62.41 Current Ratio 06/30/25 - - 03/31/25 - 8.43 12/31/24 - 9.30 Quick Ratio 06/30/25 - - 03/31/25 - 8.43 12/31/24 - 9.30 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.36 12/31/24 - 1.72 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©